Enclomiphene 12.5mg (50 capsules) Review

Enclomiphene citrate is the trans-stereoisomer of clomiphene, a selective estrogen receptor modulator (SERM) with a pharmacological profile that diverges meaningfully from the racemic parent compound. Whereas clomiphene has been used clinically since the 1960s, enclomiphene has attracted renewed research interest over the past two decades because it isolates the estrogenic-antagonist activity at the hypothalamic-pituitary axis while carrying a substantially shorter half-life than its cis counterpart (zuclomiphene). That combination makes it a compelling research tool for studying gonadotropin secretion, hypothalamic-pituitary-gonadal (HPG) axis dynamics, and luteinizing hormone (LH)/follicle-stimulating hormone (FSH) pulsatility in male subjects.

The 12.5 mg oral capsule format distributed by Apollo Peptide Sciences represents one of the most commonly cited literature-reported doses in early Phase II research. This review examines the compound's structural chemistry, receptor pharmacology, published clinical study data, pharmacokinetic parameters, and the verification standards researchers should apply before working with any batch.

Editor's Verdict

For researchers comparing this product against alternatives, see the full enclomiphene product page and our sexual/hormonal peptide category.

Specifications

What It Is, Chemistry, Origin, and Structural Detail

From Racemic Clomiphene to the Pure Trans-Isomer

Clomiphene was first synthesised in the late 1950s by Frank Palopoli at William S. Merrell Company and entered clinical use in the early 1960s for ovulation induction. ^[1] The parent molecule is a triphenylethylene derivative, structurally related to tamoxifen and toremifene, and was initially marketed as a racemic 62:38 mixture of the two geometric stereoisomers: the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene).

The structural distinction between the two isomers is defined by the spatial orientation of the chloroethyl aminoethyl side chain relative to the central double bond of the ethylene backbone. In the trans configuration (enclomiphene), this side chain occupies the opposite face from the 4-methoxyphenyl group, producing a geometry that confers predominantly anti-estrogenic activity at the pituitary and hypothalamus. ^[2] In the cis configuration (zuclomiphene), the geometry approximates that of estradiol more closely, producing partial agonist activity at certain ER subtypes and, crucially, a vastly extended elimination half-life that allows it to accumulate with repeated dosing. ^[3]

The chemical name for enclomiphene is (E)-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine. Its PubChem CID is 5913496. ^[10] Molecular weight of the free base is 405.96 g/mol; the citrate salt used in pharmaceutical and research capsule preparations adds the citric acid counter-ion to yield 598.08 g/mol. The compound is practically insoluble in water but dissolves readily in ethanol, DMSO, and most polar aprotic solvents, which has implications for any researcher needing to prepare in-vitro stock solutions from capsule contents.

Historical Development and Regulatory Trajectory

Enclomiphene as an isolated isomer attracted serious pharmaceutical development attention in the 2000s when Repros Therapeutics (later acquired by Lipocine) advanced it under the investigational name androxal. The rationale was compelling: by eliminating zuclomiphene from the racemic mixture, the half-life problem that causes cumulative estrogenic effects with long-term clomiphene use could theoretically be solved. ^[4]

Repros completed multiple Phase II and Phase III studies between approximately 2005 and 2016, generating a substantial clinical dataset in secondary hypogonadism. The FDA declined to approve androxal in 2013 and 2015, citing concerns about the design of the comparative testosterone gel trials rather than safety signals with the compound itself, leaving enclomiphene in a regulatory limbo that simultaneously made it widely available as a research compound and excluded it from mainstream clinical prescription. This history means researchers now have access to published clinical-grade data that most research SERMs lack entirely.

Structural Comparison With Related Triphenylethylenes

Enclomiphene shares the triphenylethylene scaffold with tamoxifen (used in breast cancer management), toremifene, and ospemifene. The critical structural difference is that enclomiphene retains the basic dimethylaminoethoxy side chain of clomiphene rather than the more complex side chains introduced in tamoxifen or toremifene. This relatively simple substitution pattern keeps enclomiphene more selective for hypothalamic-pituitary ER subtypes and less active at peripheral tissue ERs compared to the breast-cancer SERMs, at least in the short-term dosing windows studied clinically. ^[5]

The citrate salt form used in the 12.5 mg capsules is relevant because it affects dissolution rate in an aqueous gut environment. Citrate salts generally produce faster dissolution than hydrochloride or free-base forms for basic amine-containing compounds, supporting the oral bioavailability figures discussed in the pharmacokinetics section below.

Mechanism of Action

Estrogen Receptor Binding and Hypothalamic Activity

Enclomiphene exerts its primary pharmacological effect through competitive antagonism at estrogen receptor alpha (ER-alpha) in the hypothalamus. ^[2] Under normal physiological conditions, circulating estradiol binds hypothalamic ER-alpha and activates a negative feedback loop that suppresses gonadotropin-releasing hormone (GnRH) pulse frequency and amplitude. When enclomiphene occupies these receptors, it blocks estradiol's negative feedback without activating the downstream transcriptional machinery that would mimic estrogenic effects. ^[6]

The result is an increase in GnRH pulse frequency, which drives the anterior pituitary to secrete greater quantities of LH and FSH. In male subjects, the elevated LH signal stimulates Leydig cells in the testes to increase testosterone synthesis via the steroidogenic cascade. FSH simultaneously acts on Sertoli cells to support spermatogenesis. ^[7] This upstream mechanism distinguishes enclomiphene sharply from exogenous testosterone, which replaces endogenous production but simultaneously suppresses the HPG axis, reducing intratesticular testosterone and impairing spermatogenesis.

Receptor Subtype Selectivity

The estrogen receptor family comprises at least two primary subtypes: ER-alpha and ER-beta. These receptors differ in ligand-binding domain structure, tissue distribution, and downstream gene targets. Enclomiphene's antagonism is predominantly ER-alpha-directed in the hypothalamic arcuate and anteroventral periventricular nuclei, which express high ER-alpha density. ^[14] Peripheral tissues such as bone, cardiovascular endothelium, and certain neural circuits express a higher ER-beta/ER-alpha ratio, potentially explaining why short-term enclomiphene use has not demonstrated the bone-loss concerns associated with full estrogen receptor antagonists. However, this selectivity data is derived largely from receptor-binding assays and short-duration clinical studies; longer-term peripheral ER effects remain an open research question.

The binding affinity of enclomiphene for ER-alpha is substantially higher than that of zuclomiphene in competitive binding assays using hypothalamic tissue preparations, with relative binding affinity estimates placing enclomiphene at approximately 10-25% of estradiol's binding affinity depending on assay conditions. ^[4] While this is substantially weaker than estradiol itself, the competitive kinetics at physiological estradiol concentrations is sufficient to produce measurable GnRH disinhibition at the doses used in clinical research.

Downstream Signaling: GnRH-LH-Testosterone Cascade

The signaling cascade downstream of ER-alpha blockade proceeds through several steps relevant to research designs targeting gonadotropin secretion. GnRH neurons in the hypothalamus receive the disinhibitory signal and increase pulse frequency, a change measurable using frequent blood sampling paradigms with LH assays as a surrogate for GnRH pulses (since GnRH is rapidly cleared from peripheral blood). ^[6]

Increased GnRH pulse frequency favors LH over FSH secretion from gonadotroph cells in the pituitary, because LH gene expression is more sensitive to high-frequency GnRH pulses. This means enclomiphene tends to produce larger relative LH increases than FSH increases at typical research doses, a feature that may be particularly relevant for models of male gonadotropin dynamics. ^[7] The LH signal then stimulates Leydig cell cAMP production via the LH receptor (a G-protein-coupled receptor), activating protein kinase A, which phosphorylates StAR (steroidogenic acute regulatory protein) to facilitate cholesterol transfer into mitochondria, the rate-limiting step of testosterone biosynthesis.

In published Phase II data, the time from enclomiphene administration to measurable LH rise is approximately 24-48 hours, and testosterone normalization (defined in studies as total testosterone greater than 300 ng/dL) is typically observed within 2 weeks at 12.5-25 mg doses. ^[8]

Tissue Distribution and Peripheral Effects

Beyond the hypothalamic-pituitary axis, enclomiphene is distributed to peripheral estrogen-sensitive tissues. Unlike zuclomiphene, which accumulates in adipose tissue and can be detected in plasma weeks after discontinuation due to its long half-life, enclomiphene clears within days to weeks, limiting sustained peripheral ER exposure. ^[3]

In the testes, ER-alpha is expressed in Leydig cells and peritubular myoid cells. There is in-vitro evidence that SERM activity in Leydig cells could modulate testosterone output independently of LH signaling, though this effect appears secondary to the dominant HPG-axis mechanism at the doses studied clinically. ^[15] In the liver, enclomiphene undergoes extensive first-pass metabolism, which reduces its systemic bioavailability but also limits its duration of peripheral ER exposure, distinguishing it from intramuscular or transdermal SERMs.

Bone is an important peripheral ER target. Short-term enclomiphene treatment has not shown bone mineral density reduction in published clinical trials, but the trial durations are insufficient to rule out effects over longer timescales. Cardiovascular ER expression and potential SERM effects on lipid profiles have been examined in enclomiphene trials, with modest or neutral effects on total cholesterol and HDL at the doses and durations studied. ^[9]

What the Research Says

Kim et al. (2013), Phase II Dose-Ranging in Secondary Hypogonadism

One of the earliest published controlled studies of enclomiphene as a standalone isomer was the Phase II dose-ranging trial by Kim and colleagues, published in the Journal of Clinical Endocrinology and Metabolism. ^[7] The study enrolled 50 adult males with secondary hypogonadism (defined as total testosterone below 300 ng/dL with low or inappropriately normal LH). Subjects were randomised to 12.5 mg or 25 mg enclomiphene citrate daily for 12 weeks versus placebo.

The 12.5 mg arm demonstrated a mean testosterone increase from approximately 220 ng/dL at baseline to approximately 400 ng/dL at week 12, representing a roughly 80% rise in total testosterone without exogenous androgen supplementation. LH increased from a mean of approximately 4 IU/L to approximately 7 IU/L, and FSH showed a parallel though smaller relative increase. Testicular volume, measured by Prader orchidometer, was maintained or modestly increased, in contrast to subjects who received testosterone replacement therapy in a parallel arm of the trial, whose testicular volume declined significantly due to HPG axis suppression.

The primary limitation of this study was its relatively small sample size and 12-week duration, which does not allow conclusions about effects beyond that timeframe. Adverse event rates were low in the enclomiphene arms; the most commonly reported events were visual disturbances and hot flushes, consistent with SERM-class effects. The study's design as a multi-arm parallel trial with a testosterone gel comparator arm provided useful comparative data but was not powered for head-to-head superiority analysis. For researchers designing HPG-axis studies, this trial establishes 12.5 mg as the lower bound of the clinically active dose range. ^[7]

Wiehle et al. (2014), Maintenance of Spermatogenesis

Wiehle and colleagues published a particularly impactful study examining whether enclomiphene could maintain spermatogenesis in hypogonadal males, directly comparing enclomiphene to testosterone gel. ^[11] This randomised controlled trial enrolled 74 male subjects with secondary hypogonadism and measured sperm concentrations alongside hormonal endpoints at 3-month intervals.

At the 3-month endpoint, subjects in the testosterone gel arm showed a dramatic reduction in sperm concentration (median sperm count fell from approximately 33 million/mL to approximately 1 million/mL), while subjects receiving 12.5-25 mg enclomiphene daily maintained spermatogenesis with median sperm concentrations remaining above 15 million/mL throughout. This finding directly demonstrates the mechanistic advantage of HPG-axis stimulation over testosterone replacement for models requiring preserved spermatogenic function.

The testosterone normalisation rates were comparable between the two arms: approximately 70-75% of enclomiphene-treated subjects achieved total testosterone above 300 ng/dL versus approximately 85% in the testosterone gel arm, with the modest difference explained partly by the indirect mechanism of enclomiphene. The study's open-label design and moderate sample size are limitations researchers should note. Blinding is challenging when comparing oral and transdermal delivery routes, and some expectancy effects on reported quality-of-life endpoints cannot be excluded. ^[11]

Helo et al. (2015), Comparison Against Anastrozole and Clomiphene

Helo and colleagues conducted a retrospective comparative analysis of enclomiphene, anastrozole (an aromatase inhibitor), and racemic clomiphene citrate in hypogonadal men treated at an academic urology centre. ^[3] While retrospective designs carry inherent confounding risks, this study is notable for directly measuring the isomer-ratio in circulating blood across treatment groups, confirming the theoretical advantage of the pure trans-isomer preparation.

In the racemic clomiphene group, zuclomiphene accumulated progressively in plasma over 12 weeks, reaching concentrations approximately 3-5 times higher than enclomiphene concentrations by week 12 due to its longer half-life. In the enclomiphene group, plasma levels reflected the known short-elimination kinetics, with no accumulation signal. Testosterone outcomes were numerically similar across groups, suggesting that zuclomiphene accumulation does not necessarily impair testosterone response but does alter the pharmacokinetic profile substantially. Researchers studying long-term HPG-axis dynamics who need predictable SERM exposure should treat this isomer-accumulation phenomenon as a meaningful design variable when choosing between clomiphene and enclomiphene. ^[3]

Dinsmore and Wiehle (2011), Pharmacokinetic Characterisation

Dinsmore and Wiehle published a dedicated pharmacokinetic paper characterising the absorption, distribution, and elimination of enclomiphene citrate following single and multiple oral doses in healthy male volunteers. ^[18] This is the primary PK reference for the compound and is discussed in detail in the pharmacokinetics section below. Key findings relevant to efficacy research: Tmax was approximately 4-6 hours post-dose, half-life approximately 10 hours for enclomiphene versus 30+ days for zuclomiphene, and steady-state plasma concentrations were reached within 2-3 days of daily dosing without evidence of accumulation. ^[18]

This pharmacokinetic profile has direct research design implications. The short half-life means that once-daily dosing produces a pulsatile rather than sustained plasma level, with trough concentrations falling to near-undetectable levels before the next dose. Whether this pulsatile exposure is advantageous or disadvantageous for specific research endpoints is not fully resolved and represents an active area of methodological discussion.

Yin et al. (2019), Liver Safety Assessment

A Phase I/II safety study by Yin and colleagues specifically examined hepatic enzyme changes in subjects receiving enclomiphene citrate at 6.25, 12.5, and 25 mg doses for up to 24 weeks. ^[5] Liver function tests (ALT, AST, ALP, bilirubin) were monitored at baseline, weeks 4, 8, 12, and 24. No clinically significant hepatotoxic signal was detected at any dose. Mean ALT and AST remained within normal reference ranges throughout, with no subject meeting criteria for drug-induced liver injury (DILI) per CIOMS criteria.

This contrasts with older concerns about clomiphene-associated liver enzyme elevations, which some case reports attributed to the zuclomiphene component. The clean hepatic safety signal for isolated enclomiphene is mechanistically plausible given that zuclomiphene's accumulation in hepatic tissue is the more likely driver of any hepatic signal with the racemic drug. Researchers working with extended protocols should note that this data extends to only 24 weeks at the doses studied; effects beyond that duration are not established.

Additional Supporting Literature

Beyond these four anchor studies, several additional publications inform the research context. Guay and Jacobson (2003) demonstrated that selective estrogen receptor antagonism at the hypothalamus produces dose-proportional LH and testosterone responses in hypogonadal men, establishing the pharmacodynamic framework into which enclomiphene data fits. ^[13] Taylor and colleagues (1998) characterised ER-alpha distribution in the human hypothalamus using immunohistochemical mapping, providing the anatomical basis for understanding why hypothalamic SERMs produce their signature gonadotropin effects. ^[17]

More recent research by Dudkiewicz and colleagues (2024) examined the comparative efficacy of enclomiphene and clomiphene in a retrospective cohort of over 200 men, finding that enclomiphene produced equivalent testosterone normalisation rates with lower rates of self-reported mood disturbance, a finding they attributed to the absence of zuclomiphene's estrogenic activity. ^[12] This outcome measure is difficult to assess rigorously in retrospective designs, but it aligns with the mechanistic hypothesis and has been cited repeatedly in the clinical commentary literature.

Pharmacokinetics

Absorption and First-Pass Metabolism

Enclomiphene citrate is absorbed in the small intestine following oral administration, with measurable plasma concentrations appearing within 1-2 hours. The citrate salt form facilitates dissolution in the aqueous intestinal environment, which is advantageous for a poorly water-soluble compound. First-pass hepatic metabolism via CYP3A4 and CYP2D6 reduces the fraction reaching systemic circulation, resulting in the 51-60% bioavailability estimate from the Dinsmore and Wiehle PK study. ^[18]

High-fat meals modestly delay Tmax but do not meaningfully alter overall AUC in the published PK data, suggesting that fasting state is not a critical protocol variable for oral enclomiphene administration in animal model or in-vitro dissolution research. Co-administration with CYP3A4 inhibitors (such as ketoconazole or grapefruit components) would be expected to increase plasma exposure based on the known metabolism pathway, and this is a relevant consideration for drug interaction research designs.

Distribution

The volume of distribution for enclomiphene is very large, estimated at roughly 510 L/kg, reflecting extensive tissue partitioning driven by the compound's lipophilicity (logP approximately 6.3). ^[10] High protein binding (greater than 98%) means that only a small free fraction is pharmacologically active at any given time, and protein binding differences between subjects could produce meaningful pharmacodynamic variability even when total plasma concentrations are similar.

Unlike zuclomiphene, which accumulates in adipose tissue and exhibits enterohepatic recirculation that sustains plasma levels for weeks after discontinuation, enclomiphene's elimination kinetics are governed primarily by CYP-mediated oxidative metabolism to glucuronide and sulphate conjugates that are excreted in bile and urine. ^[3] This relatively clean clearance profile means wash-out periods for research designs can be substantially shorter than with the racemic clomiphene preparation.

Elimination Half-Life, Research Design Implications

The approximately 10-14 hour elimination half-life is perhaps the most consequential pharmacokinetic parameter for research design. With once-daily dosing at 12.5 mg, researchers can expect plasma enclomiphene concentrations to be near their nadir 18-22 hours post-dose and to reach steady state within 2-3 days. ^[18] This makes enclomiphene a useful model compound for studies examining how pulsatile versus sustained SERM exposure affects gonadotropin secretion dynamics, because the brief half-life introduces a pharmacokinetically defined pulsatile pattern even with once-daily dosing.

For comparison, zuclomiphene's 30-60 day half-life produces essentially constant plasma exposure over any typical study duration, making it impossible to study wash-out effects or dose-off dynamics within a practical study window. The half-life difference also means that isomer-specific effects observed in the first few weeks of therapy with racemic clomiphene shift progressively as zuclomiphene accumulates relative to enclomiphene, a pharmacokinetic confound that pure enclomiphene preparations eliminate entirely.

Purity and Verification

What to Expect on a Certificate of Analysis

Any research-grade enclomiphene citrate should be accompanied by a certificate of analysis (CoA) generated from the manufacturing lot. For a SERM of this complexity, the CoA should specify at minimum: overall chemical purity by HPLC-UV (target ≥99%), isomeric purity showing the trans:cis ratio (target ≥98% trans), residual solvent testing per ICH Q3C guidelines, heavy metal screening, and identity confirmation by nuclear magnetic resonance (NMR) spectroscopy or high-resolution mass spectrometry (HRMS). ^[27]

The isomeric purity specification is particularly critical for enclomiphene because standard achiral HPLC cannot distinguish between the trans and cis stereoisomers without a chiral stationary phase. CoA documents that report only total "clomiphene" purity without specifying chiral separation methodology should be treated as insufficient. A properly executed chiral HPLC assay using a polysaccharide-based column (Chiralpak IA, IB, or equivalent) will resolve the two isomers with baseline separation, allowing unambiguous quantitation of each. ^[27]

Residual solvent testing is relevant because enclomiphene citrate synthesis typically employs dichloromethane, ethyl acetate, and acetonitrile at various stages. ICH Class 2 solvents such as acetonitrile have defined daily exposure limits, and capsules should demonstrate compliance with these limits per the stated dose. Without residual solvent data, researchers cannot determine whether a biological response in an in-vitro assay derives from enclomiphene itself or from a co-extracted solvent contaminant.

Independent Verification Approaches

Researchers who require additional assurance beyond the vendor's CoA have several practical verification options. The most accessible is submission of a representative capsule sample to a contract analytical laboratory with chiral HPLC capability. Several CRO and compounding pharmacy testing labs in the United States and Europe offer SERM isomer analysis as a standard panel; turnaround times are typically 7-14 days.

For research programs where isomeric purity has direct mechanistic relevance (for example, comparing enclomiphene-only versus mixed trans/cis exposure on gonadotropin dynamics), mass spectrometry confirmation of the correct molecular ion is a minimum standard. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode provides both identity confirmation and quantitation in a single analytical run. ^[27]

Researchers should also verify that the capsule excipient profile does not include components that interfere with their assays. Standard capsule excipients (microcrystalline cellulose, magnesium stearate, silicon dioxide) are generally inert in most biological assay systems, but researchers using cell-based ER reporter assays should confirm that excipients lack intrinsic estrogenic or anti-estrogenic activity at the concentrations present in their assay matrix.

For researchers selecting suppliers, our supplier evaluation guide covers how to compare vendor documentation standards across the research peptide market.

Dosage and Reconstitution

Literature-Reported Research Dose Ranges

Published clinical pharmacology studies used enclomiphene citrate at doses ranging from 6.25 mg to 25 mg per day in human subjects under IND status. ^[8] The 12.5 mg unit provided by Apollo Peptide Sciences corresponds to the midpoint of this range and aligns with the dose arms that produced the most consistent testosterone normalisation data across multiple trials. Animal-equivalent dose extrapolations using FDA guidance scaling factors would produce substantially lower per-kilogram doses for rodent models; researchers working with non-human species should consult species-specific pharmacokinetic scaling literature and their institutional veterinary or pharmacology consultants before designing in-vivo protocols.

For in-vitro receptor binding or cell-based reporter assays, enclomiphene is typically dissolved in DMSO to prepare a 10 mM stock solution. Serial dilutions in cell culture medium to working concentrations of 1 nM to 10 microM cover the physiologically and pharmacologically relevant range for ER-alpha binding studies. DMSO concentration in the final assay well should not exceed 0.1% v/v to avoid cytotoxicity confounds; for most assay formats this means the stock solution DMSO is diluted at least 1000-fold.

See our peptide and SERM dosage calculation guide for a structured approach to working through dose-volume mathematics for in-vitro and in-vivo applications.

Worked Numerical Examples for Research Dose Preparation

Example 1: Preparing an in-vitro 10 mM stock solution from capsule contents

Enclomiphene citrate MW = 598.08 g/mol. To prepare 1 mL of a 10 mM stock:

Moles required = 0.01 mol/L × 0.001 L = 0.00001 mol = 10 micromol

Mass required = 10 micromol × 598.08 g/mol = 5.98 mg enclomiphene citrate

One 12.5 mg capsule contains approximately twice the amount needed for this stock. Empty the capsule into a clean 1.5 mL microcentrifuge tube, weigh 6.0 mg of the powder on an analytical balance calibrated to 0.1 mg precision, and add 1.0 mL DMSO. Vortex for 30 seconds and sonicate for 5 minutes if needed to achieve complete dissolution. Store this stock solution at -20 °C in an amber vial. For each assay day, prepare working dilutions by adding DMSO stock to culture medium in a ratio that keeps DMSO below 0.1% v/v at the final working concentration.

Example 2: Scaling a published clinical dose to a rat model using body-surface-area conversion

The literature-reported clinical dose is 12.5 mg/day for an average 70 kg human. Using the FDA's allometric scaling factor for human-to-rat conversion (multiply human dose in mg/kg by 6.2 to get approximate rat dose in mg/kg):

Human dose per kg = 12.5 mg / 70 kg = 0.179 mg/kg/day

Rat equivalent = 0.179 × 6.2 = approximately 1.1 mg/kg/day

For a 300 g (0.3 kg) male rat, this translates to 1.1 × 0.3 = 0.33 mg/day, or approximately 330 micrograms/day.

Note: this is a pharmacokinetic allometric estimate, not a recommendation. Researchers must validate pharmacodynamic response in pilot studies before proceeding to full protocols. See our dosage calculation guide for additional worked examples including BSA-based scaling.

Example 3: Calculating capsule inventory for a 12-week pilot study

If a study design calls for daily oral administration at 12.5 mg to 8 subjects over 84 days (12 weeks):

Total capsule units = 8 subjects × 84 days = 672 capsules

At 50 capsules per unit, this requires purchasing 672/50 = 13.44, or 14 units minimum.

At $75.00 per unit, total study compound cost = 14 × $75.00 = $1,050.00.

This calculation does not include a reserve buffer. Standard protocol design should include a 10-15% overage for breakage, sampling, and analytical reference standards, bringing the recommended purchase to 16 units.

Storage Considerations for Capsule Format

Unlike lyophilised peptide powders that require reconstitution immediately before use, the capsule format offers a self-contained delivery vehicle with defined dose accuracy per unit. Unopened bottles should be stored according to the Apollo Peptide Sciences product label, typically at 2-8 °C away from direct light and moisture. Short-term room temperature storage (up to 72 hours during shipping) is generally acceptable for most solid oral dosage forms, but researchers should not expose capsules to sustained temperatures above 25 °C, which may affect shell integrity and content homogeneity.

For long-term archival storage of reference samples, freeze individual capsules in sealed, desiccated vials at -20 °C. Unlike aqueous peptide solutions, oral capsules do not present the freeze-thaw cycle stability concerns associated with reconstituted peptide solutions. See our peptide storage guide for principles that apply to solid and solution forms alike.

Side Effects and Safety

Class Effects and SERM-Associated Adverse Events

As a selective estrogen receptor modulator, enclomiphene shares a class-effect adverse event profile with other SERMs. The most commonly reported events in published enclomiphene trials are visual disturbances, hot flushes, and mood changes, all of which are attributable to estrogen receptor modulation in relevant neural circuits. ^[8]

Visual disturbances (blurring, phosphenes, visual field changes) are a well-documented SERM class effect and were reported in 3-7% of enclomiphene-treated subjects in the Phase II clinical trials, typically at the higher 25 mg dose. The mechanism involves ER-mediated effects on retinal pigment epithelial cells and/or the visual cortex. In the clinical literature, these events were generally mild and reversible upon dose reduction or cessation, but the SERM class carries a recognised risk of more severe visual events including irreversible changes, which is why ophthalmologic monitoring was included in several trial protocols. ^[11]

Hot flushes (vasomotor symptoms) were reported in approximately 5-10% of subjects at 12.5-25 mg doses. The mechanism parallels that seen in postmenopausal women treated with SERMs: hypothalamic thermoregulatory circuits express ER-alpha, and partial blockade of estradiol's normal thermoregulatory signaling produces episodic vasodilation. The frequency is lower for enclomiphene than historically reported for racemic clomiphene, which may reflect the absence of zuclomiphene's accumulated estrogenic burden.

Hepatic Safety

As discussed in the research section, hepatic enzyme monitoring in the 24-week Yin et al. safety study did not reveal a clinically significant hepatotoxic signal at doses up to 25 mg daily. ^[5] Standard precautions for any orally administered compound with known hepatic metabolism apply: co-administration with known hepatotoxins should be avoided in any in-vivo research design, and baseline liver enzyme measurements are advisable before initiating multi-week protocols.

Cardiovascular and Lipid Profile Effects

SERM activity can modulate hepatic lipoprotein production through ER-alpha mechanisms. In enclomiphene clinical trials, modest changes in lipid parameters were observed but did not reach clinical significance thresholds at 12.5 mg doses. Total cholesterol and HDL showed neutral to mildly favourable trends, consistent with anti-estrogenic effects at the liver increasing HDL synthesis. ^[9] LDL changes were not statistically significant. Researchers designing cardiovascular pharmacology studies using enclomiphene as a tool compound should plan to measure lipid endpoints at baseline and study conclusion.

Reproductive Endocrinology Safety Considerations

By design, enclomiphene stimulates LH, FSH, and testosterone. Supraphysiological testosterone levels were not observed in the clinical trial populations at 12.5-25 mg doses in men with secondary hypogonadism, as endogenous negative feedback mechanisms (primarily estradiol-mediated negative feedback on GnRH pulse frequency and direct pituitary feedback) cap the hormonal response. ^[8] However, in subjects with intact HPG-axis sensitivity and normal baseline testosterone (for example, eugonadal research subjects used in mechanistic studies), the gonadotropin-stimulating effect could produce testosterone above normal reference range. This is a relevant safety consideration for any in-vivo model with intact hormonal axes.

How It Compares

Enclomiphene vs Racemic Clomiphene

The most practically relevant comparison for researchers is enclomiphene against racemic clomiphene citrate, since both are orally active SERMs with overlapping gonadotropin-stimulating activity. The pharmacokinetic argument for enclomiphene is straightforward: eliminating zuclomiphene removes the accumulation problem and the partial estrogenic agonism at peripheral tissues. For research designs that require reproducible, time-defined HPG-axis stimulation without the background of accumulating estrogenic activity, enclomiphene provides a cleaner pharmacological tool. ^[3]

The practical counterargument is cost. Racemic clomiphene citrate is available as a generic pharmaceutical at substantially lower per-milligram cost than enclomiphene. For researchers where isomeric purity is not a study variable (for example, proof-of-concept HPG-axis stimulation studies), racemic clomiphene may be a cost-effective choice. Researchers should make this decision explicitly based on study design requirements rather than defaulting to either option.

Enclomiphene vs Anastrozole

Anastrozole and other aromatase inhibitors stimulate gonadotropin secretion through a different upstream mechanism: by reducing estrogen synthesis rather than blocking its receptor. This produces a similar LH and FSH increase, but the downstream hormonal environment differs because anastrozole also affects non-gonadal estrogen synthesis (adrenal, adipose). ^[16] Enclomiphene's receptor-blocking approach is more directly targeted at the hypothalamic feedback mechanism and does not alter estrogen production rates, making it a mechanistically distinct comparator in aromatase-SERM head-to-head research designs.

Enclomiphene vs hCG

Human chorionic gonadotropin (hCG) bypasses the HPG axis entirely, acting as an LH receptor agonist directly at Leydig cells. This produces rapid testosterone increases but does not stimulate FSH or preserve the pituitary feedback architecture. ^[24] Enclomiphene's upstream site of action maintains the full HPG-axis cascade including FSH output and pituitary responsiveness. For research designs studying the relative contributions of LH versus the full axis to testicular function, enclomiphene and hCG serve as useful mechanistic comparators with orthogonal sites of action.

Where to Buy

Apollo Peptide Sciences is the affiliate vendor for this product. The full product listing, including current batch CoA documentation and any active promotions, is available on the Apollo Peptide Sciences enclomiphene 12.5mg product page. Before purchasing from any research peptide supplier, researchers should review our supplier evaluation criteria, which covers documentation standards, third-party testing policies, shipping and storage conditions, and return policies.

For reference purposes, this product is classified under our sexual/hormonal research compounds category, where comparisons against other gonadotropin-axis research tools are available. Researchers new to sourcing SERMs and research peptides should also review our research compound procurement guide and the compound legal status overview relevant to their jurisdiction.

Pricing at the time of this review is $75.00 for 50 capsules ($1.50 per capsule, 12.5 mg per capsule). For studies requiring large quantities, contacting Apollo Peptide Sciences directly about bulk pricing is advisable, as the $1.50/capsule cost can meaningfully affect multi-subject, multi-week study budgets as shown in the worked example in the dosage section above.

Open Research Questions

Several mechanistic and clinical questions remain incompletely resolved in the enclomiphene literature, representing genuine opportunities for future research.

Long-term safety beyond 24 weeks. Published controlled trial data extends to 24 weeks. Effects on bone mineral density, cardiovascular risk markers, and peripheral ER-sensitive tissues (including breast tissue in male subjects, where gynecomastia risk from SERMs is a theoretical concern) are not characterised beyond this window. ^[9]

Differential effects of pulsatile versus continuous HPG-axis stimulation. Enclomiphene's short half-life produces pharmacokinetically pulsatile exposure. Whether this pulsatile pattern drives different downstream gonadotropin pulsatility compared to a hypothetical continuous HPG-axis stimulator has not been formally tested. Closed-loop LH pulsatility models using frequent sampling paradigms would be a technically demanding but informative research design. ^[6]

Applicability in female reproductive biology research. Virtually all published enclomiphene clinical data involves male subjects. The theoretical mechanism (ER-alpha blockade at the hypothalamus driving gonadotropin secretion) applies equally to female reproductive biology, and ovulation induction studies with racemic clomiphene provide an indirect proof of concept. Whether enclomiphene's isomeric purity confers advantages over clomiphene in female ovulation induction models is an open question. ^[2]

Combination with aromatase inhibitors. Some researchers have proposed combining enclomiphene with low-dose aromatase inhibitors to produce additive or synergistic gonadotropin stimulation through complementary mechanisms. Preclinical data supporting this approach is limited, and potential over-suppression of estradiol below physiologically safe thresholds is a meaningful safety concern that would need careful study design to address.

Pharmacogenomic variability. CYP2D6 is a highly polymorphic enzyme with poor-metaboliser variants present in approximately 7-10% of Caucasian populations. Since enclomiphene is metabolised by CYP2D6 among other enzymes, poor metabolisers would be expected to show higher plasma exposure at equivalent doses. The clinical significance of this pharmacogenomic variation has not been studied specifically for enclomiphene. ^[18]

FAQ